Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...

DXd-THP achieved a pCR rate of 67.3% versus 56.3% with ddAC-THP, "the highest reported pCR rate in HER2-positive early breast ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6 mg/kg dose into the phase 3 part of the trial. The ORR ...

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

High School DxD Season 3 was notably the final season produced under TNK, and more notably featured some material that was not from the original light novel releases. High School DxD Hero then finally ...

New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

High School DxD just started its much anticipated fourth season, High School DxD Hero and fans have noticed quite a bit about the series’ big return to screens. Along with the changing art style ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...